The promise of stem cells, along with the controversy surrounding it, has made the industry a hot-button issue for many. Despite that promise, we have yet to see huge applicable benefits to humans. That could be changing. Cloning embryonic stem cells could mark a dramatic shift and improve on what is already a nascent process.
In this video, health-care analyst David Williamson discusses this breakthrough and what it means for investors interested in stem cell stocks.
Another topic health-care investors need to keep up on is Obamacare, as the law will undoubtedly have far-reaching effects. The Motley Fool's new free report, "Everything You Need to Know About Obamacare," lets you know how your health insurance, your taxes, and your portfolio will be affected. Click here to read more.